News & Updates

Pimavanserin for dementia-related psychosis: to continue or not?
Pimavanserin for dementia-related psychosis: to continue or not?
01 Oct 2021 byAudrey Abella

In individuals with dementia-related psychosis (DRP) who had a response to the oral 5-HT2A* inverse agonist and antagonist pimavanserin, an atypical antipsychotic agent, the risk of relapse was lower among those who continued the drug vs those who stopped it, the phase III HARMONY trial suggests.

Pimavanserin for dementia-related psychosis: to continue or not?
01 Oct 2021
Blood pressure variability implicated in dementia risk
Blood pressure variability implicated in dementia risk
01 Oct 2021